{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:40:09Z","timestamp":1792708809448,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"DOI":"10.1186\/s12877-026-08036-y","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:33:54Z","timestamp":1785144834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of azacitidine combined with venetoclax on inflammatory markers and overall response rate in elderly patients with newly diagnosed acute myeloid leukemia"],"prefix":"10.1186","volume":"26","author":[{"given":"Hui-Fang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Guang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"8036_CR1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1080\/10428194.2024.2367040","volume":"65","author":"A Alhajahjeh","year":"2024","unstructured":"Alhajahjeh A, Bewersdorf JP, Bystrom RP, Zeidan AM, Shimony S, Stahl M. Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome. Leuk Lymphoma. 2024;65:1541\u201351.","journal-title":"Leuk Lymphoma"},{"key":"8036_CR2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cll.2017.07.003","volume":"37","author":"X Chen","year":"2017","unstructured":"Chen X, Cherian S. Acute Myeloid Leukemia Immunophenotyping by Flow Cytometric Analysis. Clin Lab Med. 2017;37:753\u201369.","journal-title":"Clin Lab Med"},{"key":"8036_CR3","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6:e441.","journal-title":"Blood Cancer J"},{"key":"8036_CR4","unstructured":"Pelcovits A, Niroula R Acute Myeloid Leukemia: A Review. R I, Med J (2013). 2020; 103:38\u201340."},{"key":"8036_CR5","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood.2024024245","volume":"145","author":"DA Sallman","year":"2025","unstructured":"Sallman DA, Stahl M. TP53-mutated acute myeloid leukemia: how can we improve outcomes? Blood. 2025;145:2828\u201333.","journal-title":"Blood"},{"key":"8036_CR6","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.3390\/curroncol29090491","volume":"29","author":"RJ Stubbins","year":"2022","unstructured":"Stubbins RJ, Francis A, Kuchenbauer F, Sanford D. Management of Acute Myeloid Leukemia: A Review for General Practitioners in Oncology. Curr Oncol. 2022;29:6245\u201359.","journal-title":"Curr Oncol"},{"key":"8036_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11912-024-01503-y","volume":"26","author":"M Wysota","year":"2024","unstructured":"Wysota M, Konopleva M, Mitchell S. Novel Therapeutic Targets in Acute Myeloid Leukemia (AML). Curr Oncol Rep. 2024;26:409\u201320.","journal-title":"Curr Oncol Rep"},{"key":"8036_CR8","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.2147\/CMAR.S271442","volume":"14","author":"Y Moreno Vanegas","year":"2022","unstructured":"Moreno Vanegas Y, Badar T. Clinical Utility of Azacitidine in the Management of Acute Myeloid Leukemia: Update on Patient Selection and Reported Outcomes. Cancer Manag Res. 2022;14:3527\u201338.","journal-title":"Cancer Manag Res"},{"key":"8036_CR9","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.21873\/anticanres.17003","volume":"44","author":"Y Baba","year":"2024","unstructured":"Baba Y, Hida N, Sambe T, Abe M, Kabasawa N, Sakai H, Yoshimura K, Fukuda T. Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience. Anticancer Res. 2024;44:2003\u20137.","journal-title":"Anticancer Res"},{"key":"8036_CR10","doi-asserted-by":"publisher","first-page":"e13807","DOI":"10.1111\/cts.13807","volume":"17","author":"AH Salem","year":"2024","unstructured":"Salem AH, Menon RM. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor. Clin Transl Sci. 2024;17:e13807.","journal-title":"Clin Transl Sci"},{"key":"8036_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-023-01437-1","volume":"16","author":"H Jin","year":"2023","unstructured":"Jin H, Zhang Y, Yu S, Du X, Xu N, Shao R, Lin D, Chen Y, Xiao J, Sun Z, Deng L, Liang X, Zhang H, Guo Z, Dai M, Shi P, Huang F, Fan Z, Yin Z, Xuan L, Lin R, Jiang X, Yu G, Liu Q. Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed\/Refractory AML: A Multicenter, Phase 2 Trial. J Hematol Oncol. 2023;16:42.","journal-title":"J Hematol Oncol"},{"key":"8036_CR12","doi-asserted-by":"crossref","unstructured":"Xu J, Dong X, Huang DCS, Xu P, Zhao Q, Chen B. Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers. Cancers (Basel). 2023;15:4957.","DOI":"10.3390\/cancers15204957"},{"key":"8036_CR13","doi-asserted-by":"crossref","unstructured":"Sedaki B, Iat A, Benachour S, Loschi M, Risso K, Abichou G, Ferrero-Vacher C, De Pooter N, Mouanes-Abelin J, Dadone-Montaudie B, Cluzeau T. Real World Experience of Azacitidine\u2009+\u2009Venetoclax in Acute Myeloid Leukemia Rigorously Following Management Guidelines from Clinical Trial. Acta Haematol. 2025; 1\u20135.","DOI":"10.1159\/000548334"},{"key":"8036_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s43018-022-00480-0","volume":"4","author":"A Lasry","year":"2023","unstructured":"Lasry A, Nadorp B, Fornerod M, Nicolet D, Wu H, Walker CJ, Sun Z, Witkowski MT, Tikhonova AN, Guillamot-Ruano M, Cayanan G, Yeaton A, Robbins G, Obeng EA, Tsirigos A, Stone RM, Byrd JC, Pounds S, Carroll WL, Gruber TA. Eisfeld AK and Aifantis I. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer. 2023;4:27\u201342.","journal-title":"Nat Cancer"},{"key":"8036_CR15","doi-asserted-by":"crossref","unstructured":"Reikvam H, Rolfsnes MG, Rolsdorph L, Sandnes M, Selheim F, Hernandez-Valladares M, Bruserud \u00d8. Ferritin in Acute Myeloid Leukemia: Not Only a Marker of Inflammation and Iron Overload, but Also a Regulator of Cellular Iron Metabolism, Signaling and Communication. Int J Mol Sci. 2025;26:5744.","DOI":"10.3390\/ijms26125744"},{"key":"8036_CR16","doi-asserted-by":"publisher","first-page":"102526","DOI":"10.1016\/j.coph.2025.102526","volume":"82","author":"B Wang","year":"2025","unstructured":"Wang B, Reville PK, Abbas HA. Therapeutic hurdles in acute myeloid leukemia: Leukemic stem cells, inflammation and immune dysfunction. Curr Opin Pharmacol. 2025;82:102526.","journal-title":"Curr Opin Pharmacol"},{"key":"8036_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12885-022-10499-2","volume":"23","author":"J Wen","year":"2023","unstructured":"Wen J, Xu F, Zhou Q, Shi L, Liu Y, Yue J, Zhang Y, Liang X. Effects of peripheral blood leukocyte count and tumor necrosis factor-alpha on early death in acute promyelocytic leukemia. BMC Cancer. 2023;23:27.","journal-title":"BMC Cancer"},{"key":"8036_CR18","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1158\/1541-7786.MCR-23-0382","volume":"21","author":"D Hou","year":"2023","unstructured":"Hou D, Zheng X, Cai D, You R, Liu J, Wang X, Liao X, Tan M, Lin L, Wang J, Zhang S, Huang H. Interleukin-6 Facilitates Acute Myeloid Leukemia Chemoresistance via Mitofusin 1-Mediated Mitochondrial Fusion. Mol Cancer Res. 2023;21:1366\u201378.","journal-title":"Mol Cancer Res"},{"key":"8036_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2147\/CMAR.S343580","volume":"14","author":"L Dou","year":"2022","unstructured":"Dou L, Shi M, Song J, Niu X, Niu J, Wei S, Li D, Bai Y, Sun K. The Prognostic Significance of C-Reactive Protein to Albumin Ratio in Newly Diagnosed Acute Myeloid Leukaemia Patients. Cancer Manag Res. 2022;14:303\u201316.","journal-title":"Cancer Manag Res"},{"key":"8036_CR20","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1182\/bloodadvances.2022009010","volume":"7","author":"CA Lachowiez","year":"2023","unstructured":"Lachowiez CA, Long N, Saultz J, Gandhi A, Newell LF, Hayes-Lattin B, Maziarz RT, Leonard J, Bottomly D, McWeeney S, Dunlap J, Press R, Meyers G, Swords R, Cook RJ, Tyner JW. Druker BJ and Traer E. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. Blood Adv. 2023;7:1899\u2013909.","journal-title":"Blood Adv"},{"key":"8036_CR21","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, D\u00f6hner H, R\u00e9cher C, Fiedler W, Yamamoto K, Wang J, Yoon SS, Wolach O, Yeh SP, Leber B, Esteve J, Mayer J, Porkka K, Ill\u00e9s \u00c1, Lemoli RM, Turgut M, Ku G, Miller C, Zhou Y, Zhang M, Chyla B, Potluri J. and DiNardo CD. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99:615\u201324.","journal-title":"Am J Hematol"},{"key":"8036_CR22","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, Gotlib J, Dupriez B, Pardanani A, Harrison C, Hoffman R, Gisslinger H, Kr\u00f6ger N, Thiele J, Barbui T, Barosi G. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395\u20138.","journal-title":"Blood"},{"key":"8036_CR23","unstructured":"Health UDo and Human Services %J Maryland USUNIoH. Common terminology criteria for adverse events (CTCAE) version 4.03. June 14, 2010. 2021."},{"key":"8036_CR24","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3892\/ol.2024.14711","volume":"28","author":"YW Chang","year":"2024","unstructured":"Chang YW, Chao WR, Lai YT, Fan FS. Furosemide\u2013induced eradication of myeloblasts via the inhibition of tumor necrosis factor\u2013\u03b1 expression in a patient with acute biphenotypic leukemia: A case report. Oncol Lett. 2024;28:578.","journal-title":"Oncol Lett"},{"key":"8036_CR25","first-page":"e24835","volume":"14","author":"S Verma","year":"2022","unstructured":"Verma S, Singh A, Yadav G, Kushwaha R, Ali W, Verma SP, Singh US. Serum Tumor Necrosis Factor-Alpha Levels in Acute Leukemia and Its Prognostic Significance. Cureus. 2022;14:e24835.","journal-title":"Cureus"},{"key":"8036_CR26","first-page":"2732","volume":"16","author":"T Chen","year":"2018","unstructured":"Chen T, Zhang J, Zeng H, Zhang Y, Zhang Y, Zhou X, Zhao D, Feng Y, Zhou H. The impact of inflammation and cytokine expression of PM2.5 in AML. Oncol Lett. 2018;16:2732\u201340.","journal-title":"Oncol Lett"},{"key":"8036_CR27","doi-asserted-by":"crossref","unstructured":"Di Francesco B, Verzella D, Capece D, Vecchiotti D, Di Vito Nolfi M, Flati I, Cornice J, Di Padova M, Angelucci A, Alesse E, Zazzeroni F. NF-\u03baB: A Druggable Target in Acute Myeloid Leukemia. Cancers (Basel). 2022;14:3557.","DOI":"10.3390\/cancers14143557"},{"key":"8036_CR28","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41375-026-02954-x","volume":"40","author":"Y Neelamraju","year":"2026","unstructured":"Neelamraju Y, Rapaport F, Gandara JA, Paudel BB, DeWolf S, Dunham N, Fan H, Lee T, Mayo MW, Othman J, Sheridan C, Sol-Church K, Solga MD, Wang L, Cripe LD, Dillon R, Kleppe M, Carroll M, Mason CE, Roboz GJ, Sun Z, Tallman MS, Zhang Y, Paietta E, Levine R, Melnick AM, Bekiranov S, Garrett-Bakelman FE. Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patients. Leukemia. 2026;40:1049\u201353.","journal-title":"Leukemia"},{"key":"8036_CR29","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s12672-024-01348-8","volume":"15","author":"X Peng","year":"2024","unstructured":"Peng X, Yu J, Tang F, Li Y, Bai J, Li L, Zhang L. Clinical efficacy and immune response of BCL-2 inhibitors combined with hypomethylating agents in the treatment of acute myeloid leukemia. Discov Oncol. 2024;15:451.","journal-title":"Discov Oncol"},{"key":"8036_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-023-01476-8","volume":"16","author":"NJ Short","year":"2023","unstructured":"Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J. Kantarjian H. A phase 1\/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol. 2023;16:73.","journal-title":"J Hematol Oncol"},{"key":"8036_CR31","doi-asserted-by":"publisher","first-page":"E422","DOI":"10.1002\/ajh.26707","volume":"97","author":"BA Jonas","year":"2022","unstructured":"Jonas BA, DiNardo C, Fracchiolla N, Pristupa A, Ishizawa K, Jin J, Konopleva M, Ofran Y, Montesinos P, Kovacsovics T, Jang JH, Kantarjian H, Duan Y, Potluri J, Werner M, Pratz KW. Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study. Am J Hematol. 2022;97:E422\u20135.","journal-title":"Am J Hematol"},{"key":"8036_CR32","first-page":"331","volume":"9","author":"V Karakus","year":"2022","unstructured":"Karakus V, Maral S, Kaya E, Gemici A, Dere Y, Sevindik OG. Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data. North Clin Istanb. 2022;9:331\u20136.","journal-title":"North Clin Istanb"},{"key":"8036_CR33","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1182\/blood-2018-10-879866","volume":"133","author":"G Huls","year":"2019","unstructured":"Huls G, Chitu DA, Havelange V, Jongen-Lavrencic M, van de Loosdrecht AA, Biemond BJ, Sinnige H, Hodossy B, Graux C, Kooy RVM, de Weerdt O, Breems D, Klein S, Kuball J, Deeren D, Terpstra W, Vekemans MC, Ossenkoppele GJ. Vellenga E and L\u00f6wenberg B. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood. 2019;133:1457\u201364.","journal-title":"Blood"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-026-08036-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-026-08036-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-026-08036-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:21:45Z","timestamp":1792707705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-026-08036-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8036"],"URL":"https:\/\/doi.org\/10.1186\/s12877-026-08036-y","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"9 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study received approval from the Institutional Review Board and Ethics Committee of the Henan Provincial People\u2019s Hospital, and was conducted in accordance to the tenets of the Declaration of Helsinki. Clinical, laboratory, and treatment-related information was collected from electronic medical records using a uniform data extraction form. Since the study utilized pre-existing, anonymized patient data and presented minimal risk to participants, the Institutional Review Board granted a waiver of informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1332"}}